Biogen, Inc. (BIIB)
250.69
-3.15
(-1.24%)
USD |
NASDAQ |
Oct 23, 16:00
247.18
-3.51
(-1.40%)
After-Hours: 20:00
Biogen Enterprise Value : 44.10B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 44.10B |
| October 22, 2026 | 44.56B |
| October 21, 2026 | 42.66B |
| October 20, 2026 | 42.98B |
| October 19, 2026 | 41.56B |
| October 16, 2026 | 41.43B |
| October 15, 2026 | 41.83B |
| October 14, 2026 | 41.46B |
| October 13, 2026 | 40.88B |
| October 12, 2026 | 40.95B |
| October 09, 2026 | 40.41B |
| October 08, 2026 | 39.33B |
| October 07, 2026 | 39.88B |
| October 06, 2026 | 39.99B |
| October 05, 2026 | 40.09B |
| October 02, 2026 | 39.55B |
| October 01, 2026 | 39.98B |
| September 30, 2026 | 40.43B |
| September 29, 2026 | 40.61B |
| September 28, 2026 | 40.85B |
| September 25, 2026 | 40.69B |
| September 24, 2026 | 40.50B |
| September 23, 2026 | 40.68B |
| September 22, 2026 | 40.36B |
| September 21, 2026 | 39.43B |
| Date | Value |
|---|---|
| September 18, 2026 | 38.90B |
| September 17, 2026 | 39.42B |
| September 16, 2026 | 38.97B |
| September 15, 2026 | 39.00B |
| September 14, 2026 | 39.17B |
| September 11, 2026 | 39.14B |
| September 10, 2026 | 38.89B |
| September 09, 2026 | 38.19B |
| September 08, 2026 | 38.46B |
| September 04, 2026 | 39.69B |
| September 03, 2026 | 40.23B |
| September 02, 2026 | 39.96B |
| September 01, 2026 | 38.98B |
| August 31, 2026 | 39.07B |
| August 28, 2026 | 39.34B |
| August 27, 2026 | 39.79B |
| August 26, 2026 | 39.72B |
| August 25, 2026 | 39.68B |
| August 24, 2026 | 39.29B |
| August 21, 2026 | 39.09B |
| August 20, 2026 | 38.73B |
| August 19, 2026 | 39.79B |
| August 18, 2026 | 38.46B |
| August 17, 2026 | 37.96B |
| August 14, 2026 | 38.06B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 569.05B |
| Gilead Sciences, Inc. | 214.93B |
| Amgen, Inc. | 280.78B |
| Ionis Pharmaceuticals, Inc. | 7.245B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 97.50M |
| Revenue (Quarterly) | 2.622B |
| Total Expenses (Quarterly) | 2.525B |
| EPS Diluted (Quarterly) | 0.6557 |
| Gross Profit Margin (Quarterly) | 61.37% |
| Profit Margin (Quarterly) | 3.72% |
| Earnings Yield | 2.25% |
| Operating Earnings Yield | 5.09% |
| Normalized Earnings Yield | 3.644 |